New Offering Designed to Help Health Plans Navigate the Anti-Cancer Drug Market to Improve Member Treatment Recommendations
National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund Atlanta, GA, May 26, 2020 — Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health...
Articles & Press
The following article is the fifth in a five-part series on The Top Five Ways for Health Plans to Manage Oncology Drug Costs While Improving Member Treatment Options.
JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Case vs. BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
The following article, written by Melissa Pozotrigo, Senior Clinical Oncology Pharmacist at Oncology Analytics, is the final of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held May 29-31, 2020.
WEBINAR: Health Plan Best Practices for Using Oncology Pharmacy Expertise to Navigate the Anti-cancer Drug Market
Date: Thursday, October 8th
11AM PDT | 2PM EDT